Data in a Phase 3 Study of First-Line Brigatinib vs. Crizotinib in NSCLC (ALTA-1L)

Data in a Phase 3 Study of First-Line Brigatinib vs. Crizotinib in NSCLC (ALTA-1L)

User Photo
Cancer-News

11 months
30 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Dr. Mohammed Jahanzeb, MD provides Health-Related Quality of Life (HRQoL) Data in a Phase 3 Study of First-Line Brigatinib vs. Crizotinib in NSCLC (ALTA-1L).
Up Next Autoplay